Back to search results

Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation · Advanced PDTC or ATC With NRAS Mutation

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China

    Contact: Study coordinator (Dongmei Ji, M.D) · jidongmei2000@hotmail.com · 021-64175590
    Contact: Study coordinator (Yu-Long Wang, M.D) · yulongwang@fudan.edu.cn
    Contact: Principal Investigator (Dongmei Ji, M.D)
    Contact: Principal Investigator (Yu-Long Wang, M.D)
    Contact: Principal Investigator (Qing-Hai Ji, M.D)
Study leads

  • Yu-Long Wang, M.D

    Principal Investigator

    Fudan University

  • Qing-Hai Ji, M.D

    Principal Investigator

    Fudan University

View source on ClinicalTrials.gov(opens in a new tab)Contact study team (email)